Director Christine A. Pellizzari filed a Form 4 with the SEC on November 10, 2026, disclosing the acquisition of 13,166 shares of Imunon, Inc. common stock on November 6, 2026, granted in lieu of cash board fees.

Key Highlights

  • Reporting person: Christine A. Pellizzari, Director of Imunon, Inc. (NASDAQ:IMNN)
  • Transaction date: November 6, 2026
  • Shares acquired: 13,166 shares of common stock, transaction code "A" (acquired)
  • Price per share: $0.845
  • Nature of grant: Stock granted in lieu of cash for a portion of board fees, per the filing's footnote
  • Beneficial ownership following transaction: 28,665 shares held directly

Imunon Director Pellizzari Acquires Shares in Lieu of Cash Board Compensation

According to the Form 4 filed on November 10, 2026, Christine A. Pellizzari, a director of Imunon, Inc., acquired 13,166 shares of the company's common stock on November 6, 2026, at a price of $0.845 per share. The filing indicates the transaction code as "A," denoting an acquisition, and the shares were reported as directly owned.

The filing's footnote states that the stock was "granted in lieu of cash for portion of board fees," meaning the shares represent a form of non-cash director compensation rather than an open-market purchase. Following this transaction, Pellizzari's total direct beneficial ownership in Imunon common stock stands at 28,665 shares, according to the filing.

The Form 4 was signed by Jeffrey W. Church as attorney in fact for Christine Pellizzari and submitted to the SEC on November 10, 2026. No derivative securities transactions were reported in Table II of the filing. The filing does not indicate that any amendment to a prior Form 4 was made.

What Was Disclosed

Imunon, Inc. director Christine A. Pellizzari disclosed the acquisition of 13,166 shares of common stock at $0.845 per share on November 6, 2026, as stock granted in lieu of cash board fees, bringing her direct beneficial ownership to 28,665 shares.